Literature DB >> 18593947

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Paolo Serafini1, Stephanie Mgebroff, Kimberly Noonan, Ivan Borrello.   

Abstract

Tumor-induced T-cell tolerance is a major mechanism that facilitates tumor progression and limits the efficacy of immune therapeutic interventions. Regulatory T cells (Treg) play a central role in the induction of tolerance to tumor antigens, yet the precise mechanisms regulating its induction in vivo remain to be elucidated. Using the A20 B-cell lymphoma model, here we identify myeloid-derived suppressor cells (MDSC) as the tolerogenic antigen presenting cells capable of antigen uptake and presentation to tumor-specific Tregs. MDSC-mediated Treg induction requires arginase but is transforming growth factor-beta independent. In vitro and in vivo inhibition of MDSC function, respectively, with NOHA or sildenafil abrogates Treg proliferation and tumor-induced tolerance in antigen-specific T cells. These findings establish a role for MDSCs in antigen-specific tolerance induction through preferential antigen uptake mediating the recruitment and expansion of Tregs. Furthermore, therapeutic interventions, such as in vivo phosphodiesterase 5-inhibition, which effectively abrogate the immunosuppressive role of MDSCs and reduce Treg numbers, may play a critical role in delaying and/or reversing tolerance induction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593947      PMCID: PMC2887390          DOI: 10.1158/0008-5472.CAN-07-6621

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Authors:  Steven J Bensinger; Patrick T Walsh; Jidong Zhang; Martin Carroll; Ramon Parsons; Jeffrey C Rathmell; Craig B Thompson; Matthew A Burchill; Michael A Farrar; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

2.  B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.

Authors:  S Weiss; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Myeloma proteins as tumor-specific antigens.

Authors:  H N Eisen; N Sakato; S J Hall
Journal:  Transplant Proc       Date:  1975-06       Impact factor: 1.066

4.  Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies.

Authors:  Katrin U Lundin; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Alexandre Corthay; Bjarne Bogen
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 5.  Derangement of immune responses by myeloid suppressor cells.

Authors:  Paolo Serafini; Carmela De Santo; Ilaria Marigo; Sara Cingarlini; Luigi Dolcetti; Giovanna Gallina; Paola Zanovello; Vincenzo Bronte
Journal:  Cancer Immunol Immunother       Date:  2003-10-30       Impact factor: 6.968

6.  Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.

Authors:  Yuanqing Liu; Jo A Van Ginderachter; Lea Brys; Patrick De Baetselier; Geert Raes; Anja B Geldhof
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

7.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

8.  Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.

Authors:  T Thomas; U B Gunnia; E J Yurkow; J R Seibold; T J Thomas
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

9.  Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes.

Authors:  C A Janeway; N Sakato; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

10.  Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells.

Authors:  L H Glimcher; K J Kim; I Green; W E Paul
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

View more
  288 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.

Authors:  Sabrin H Albeituni; Chuanlin Ding; Min Liu; Xiaoling Hu; Fengling Luo; Goetz Kloecker; Michael Bousamra; Huang-ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

4.  Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.

Authors:  Leah M Alabanza; Naomi L Esmon; Charles T Esmon; Margaret S Bynoe
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

Review 5.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

6.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Authors:  Min-Hee Oh; Im-Hong Sun; Liang Zhao; Robert D Leone; Im-Meng Sun; Wei Xu; Samuel L Collins; Ada J Tam; Richard L Blosser; Chirag H Patel; Judson M Englert; Matthew L Arwood; Jiayu Wen; Yee Chan-Li; Lukáš Tenora; Pavel Majer; Rana Rais; Barbara S Slusher; Maureen R Horton; Jonathan D Powell
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

7.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

8.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

9.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion.

Authors:  S Peter; G Bak; Kevin Hart; Brent Berwin
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.